Loomis Sayles & Co. L P Sells 258,394 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Loomis Sayles & Co. L P lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 37.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 438,306 shares of the medical research company's stock after selling 258,394 shares during the quarter. Loomis Sayles & Co. L P owned approximately 0.24% of IQVIA worth $86,132,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in shares of IQVIA during the 4th quarter worth about $236,120,000. American Century Companies Inc. lifted its position in IQVIA by 396.0% during the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after acquiring an additional 905,960 shares during the last quarter. FMR LLC grew its position in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, Nordea Investment Management AB boosted its stake in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Institutional investors own 89.62% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on IQV shares. UBS Group reduced their target price on shares of IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. JPMorgan Chase & Co. dropped their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Finally, William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $249.05.

IQVIA Trading Down 2.3 %

Shares of IQV stock traded down $4.07 during trading hours on Monday, hitting $173.33. 799,933 shares of the company were exchanged, compared to its average volume of 1,297,510. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $169.54 and a fifty-two week high of $253.84. The company has a 50 day simple moving average of $193.15 and a two-hundred day simple moving average of $206.05. The firm has a market cap of $30.56 billion, a P/E ratio of 23.10, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.